Tablet disintegration5/30/2023 Osteoarthritis (OA) is the most commonly known type of arthritis affecting middle aged and elderly populations worldwide. Non-steroidal anti-inflammatory drugs COX-II,Įuropean Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis IL-1β,īiopharmaceutics Classification System, class II GIT,ĭissolution efficiency % at 10 minutes DE (30 min) %,ĭissolution efficiency % at 30 minutes MDT, This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.ĭata Availability: All relevant data are within the manuscript and its Supporting Information files.įunding: The authors received no specific funding for this work.Ĭompeting interests: No authors have competing interests. Received: SeptemAccepted: DecemPublished: December 31, 2020Ĭopyright: © 2020 Fouad et al. PLoS ONE 15(12):Įditor: Muhammad Hanif, Bahauddin Zakariya University, PAKISTAN It could be concluded that optimized ODT could be promising for enhanced dissolution and rapid absorption of DCN from the oral cavity.Ĭitation: Fouad SA, Malaak FA, El-Nabarawi MA, Abu Zeid K (2020) Development of orally disintegrating tablets containing solid dispersion of a poorly soluble drug for enhanced dissolution: In-vitro optimization/ in-vivo evaluation. In- vivo anti-inflammatory effect of optimized ODT, using rat paw edema revealed significant increase in edema inhibition (p < 0.0465) and promoted onset of action compared to Diacerein ® capsules at 0.5 hr. The optimized ODT showed 1.50 and 1.12 fold increase in DE (10 min)% and DE (30 min)%, respectively and 2 fold decrease in MDT, compared to Diacerein ® capsules. Dissolution parameters dissolution efficiency percent at 10 (DE (10 min)%) and 30 (DE (30 min)%) min and mean dissolution time (MDT) were determined. Prepared ODTs were evaluated for physical characteristics, in- vitro drug release, disintegration and wetting times. Therefore, in this study orally disintegrating tablets (ODTs) loaded with optimized DCN solid dispersion system were prepared using different co-processed excipients (Prosolv ® ODT, Pharmaburst ® 500 and F-melt ®), aiming to achieve improved solubility, rapid absorption and consequently limited amount of rhein reaching the colon. Unabsorbed colonic DCN is converted into rhein, which is responsible for laxation as a main side effect of DCN treatment. Diacerein (DCN), a potent anti-inflammatory API used to treat osteoarthritis yet, it suffers from poor water solubility which affects its oral absorption.
0 Comments
Leave a Reply. |